Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LysM and putative peptidoglycan-binding domain-containing protein 3 (LYSMD3) is an evolutionarily conserved type II integral membrane protein that contains a lysin motif (LysM) domain, which is commonly associated with peptidoglycan binding[1][4]. In human and mouse cells, LYSMD3 is localized primarily to the Golgi apparatus and is essential for Golgi structural integrity[4][6]. Although its LysM domain suggests a potential role in innate immune functions or recognition of bacterial cell wall components, genetic knockout studies in mice have not established a clear in vivo physiological function for LYSMD3 and no deficiencies in immune response, inflammation, or intestinal microbiome were observed with its loss[1][2]. Orthologs exist across multiple species, highlighting evolutionary conservation, but no direct link to human disease or actionable therapeutic targeting is currently known[1][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on LysM and putative peptidoglycan-binding domain-containing protein 3 (LYSMD3).